Incorporating alternative design clinical trials in network meta-analyses

Area of Science:

• Clinical Epidemiology
• Biostatistics

Background:

• Network meta-analysis (NMA) enables simultaneous comparison of multiple interventions, but unique clinical trial designs pose challenges for data integration.
• Ethical considerations and established drug efficacies limit placebo-controlled or older drug class trials, necessitating alternative study designs.
• Ulcerative colitis is used as a case study to demonstrate a method for incorporating data from these unique trials into NMA.

Purpose of the Study:

• To present a method for converting data from alternative randomized clinical trial designs into a standard parallel format suitable for NMA.
• To illustrate how data from unique trial designs can be used to populate treatment networks for comparative effectiveness research.
• To enhance the precision of treatment effect estimates in NMA by including a wider range of evidence.

Main Methods:

• Data from the PURSUIT trial were converted into a parallel design for NMA.
• Imputation techniques were used to address missing data for golimumab arms and placebo maintenance response.
• Data from the PURSUIT trial were combined with ACT-1 and ULTRA-2 trial data to impute missing information.

Main Results:

• A methodology was demonstrated to convert non-parallel trial data into a parallel format.
• Imputation strategies were successfully applied to handle missing data points in the treatment network.
• The conversion process allowed for the inclusion of data from alternative trial designs into the NMA.

Conclusions:

• Methods were successfully demonstrated for converting alternative study designs into conventional parallel randomized clinical trials.
• These conversions facilitate indirect treatment comparisons, broadening the evidence base.
• The approach enhances the precision of treatment effect estimates in NMA.